PCSK9 levels in abdominally obese men: Association with cardiometabolic risk profile and effects of a one-year lifestyle modification program

Atherosclerosis

Volumn 236, Issue 2, 2014, Pages 321-326

  Arsenault, Benoit J ^a,b   Pelletier Beaumont, Emilie ^a,b   Alméras, Natalie ^a   Tremblay, Angelo ^a,b   Poirier, Paul ^a,b   Bergeron, Jean ^c   Després, Jean Pierre ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c University Laval   (Canada)

Author keywords

Insulin resistance; Nutrition; Obesity; PCSK9; Physical activity

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGHLY SENSITIVE C REACTIVE PROTEIN; INSULIN; INTERLEUKIN 6; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ADIPOCYTOKINE; BIOLOGICAL MARKER; LOW DENSITY LIPOPROTEIN; PCSK9 PROTEIN, HUMAN;

ABDOMINAL OBESITY; ADULT; AGED; ARTICLE; ASSOCIATION; BODY FAT DISTRIBUTION; BODY MASS; CARDIOMETABOLIC RISK; CARDIORESPIRATORY FITNESS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIETARY INTAKE; DYSLIPIDEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FAT FREE MASS; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIFESTYLE MODIFICATION; LIPID METABOLISM; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL COUNSELING; PARTICLE SIZE; PHYSICAL ACTIVITY; PROTEIN BLOOD LEVEL; SEDENTARY LIFESTYLE; SUBCUTANEOUS FAT; WAIST CIRCUMFERENCE; ANTHROPOMETRY; BLOOD; CARDIOVASCULAR DISEASES; COMORBIDITY; DYSLIPIDEMIAS; ENZYMOLOGY; EXERCISE TEST; FITNESS; FOLLOW UP; INFLAMMATION; KINESIOTHERAPY; LIFESTYLE; LOW CALORY DIET; LOW FAT DIET; MIDDLE AGED; OBESITY, ABDOMINAL; PERSONALIZED MEDICINE; RISK FACTOR; ULTRASTRUCTURE; WEIGHT REDUCTION;

ADIPOKINES; ADULT; AGED; ANTHROPOMETRY; BIOMARKERS; CARDIOVASCULAR DISEASES; COMORBIDITY; DIET, FAT-RESTRICTED; DIET, REDUCING; DYSLIPIDEMIAS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXERCISE TEST; EXERCISE THERAPY; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; INSULIN RESISTANCE; LIFE STYLE; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OBESITY, ABDOMINAL; PARTICLE SIZE; PHYSICAL FITNESS; PRECISION MEDICINE; PROPROTEIN CONVERTASES; RISK FACTORS; SEDENTARY LIFESTYLE; SERINE ENDOPEPTIDASES; WEIGHT LOSS;

EID: 84907075451     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.07.010     Document Type: Article

References (32)

1. Abifadel M., Varret M., Rabes J.P., Allard D., Ouguerram K., Devillers M., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003, 34:154-156.
2. Nordestgaard B.G., Chapman M.J., Humphries S.E., Ginsberg H.N., Masana L., Descamps O.S., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European atherosclerosis society. Eur Heart J 2013, 34:3478-3490a. European atherosclerosis society consensus P.
3. Deloukas P., Kanoni S., Willenborg C., Farrall M., Assimes T.L., Thompson J.R., et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet 2013, 45:25-33.
4. Cohen J.C., Boerwinkle E., Mosley T.H., Hobbs H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006, 354:1264-1272.
5. Benn M., Nordestgaard B.G., Grande P., Schnohr P., Tybjaerg-Hansen A. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol 2010, 55:2833-2842.
6. Lagace T.A., Curtis D.E., Garuti R., McNutt M.C., Park S.W., Prather H.B., et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest 2006, 116:2995-3005.
7. Zhang D.W., Lagace T.A., Garuti R., Zhao Z., McDonald M., Horton J.D., et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat a of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem 2007, 282:18602-18612.
8. Denis M., Marcinkiewicz J., Zaid A., Gauthier D., Poirier S., Lazure C., et al. Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice. Circulation 2012, 125:894-901.
9. Roubtsova A., Munkonda M.N., Awan Z., Marcinkiewicz J., Chamberland A., Lazure C., et al. Circulating proprotein convertase subtilisin/kexin 9 (pcsk9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arterioscler Thromb Vasc Biol 2011, 31:785-791.
10. Mbikay M., Sirois F., Mayne J., Wang G.S., Chen A., Dewpura T., et al. PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. FEBS Lett 2010, 584:701-706.
11. Langhi C., Le May C., Gmyr V., Vandewalle B., Kerr-Conte J., Krempf M., et al. PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion. Biochem Biophys Res Commun 2009, 390:1288-1293.
12. Chernogubova E., Strawbridge R., Mahdessian H., Malarstig A., Krapivner S., Gigante B., et al. Common and low-frequency genetic variants in the PCSK9 locus influence circulating PCSK9 levels. Arterioscler Thromb Vasc Biol 2012, 32:1526-1534.
13. Baass A., Dubuc G., Tremblay M., Delvin E.E., O'Loughlin J., Levy E., et al. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin Chem 2009, 55:1637-1645.
14. Lemieux I., Pascot A., Couillard C., Lamarche B., Tchernof A., Alme´ras N., et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?. Circulation 2000, 102:179-184.
15. Nazare J.A., Smith J., Borel A.L., Alme´ras N., Tremblay A., Bergeron J., et al. Changes in both global diet quality and physical activity level synergistically reduce visceral adiposity in men with features of metabolic syndrome. J Nutr 2013, 143:1074-1083.
16. The airlie (va) consensus conference: standardization of anthropometric measurements 1988, 39-80. Human Kinetics Publishers, Champaign, IL. T.R.A. Lohman, R. Martorel (Eds.).
17. van der Kooy K., Leenen R., Seidell J.C., Deurenberg P., Visser M. Abdominal diameters as indicators of visceral fat: comparison between magnetic resonance imaging and anthropometry. Br J Nutr 1993, 70:47-58.
18. Ferland M., Despre´s J.P., Tremblay A., Pinault S., Nadeau A., Moorjani S., et al. Assessment of adipose tissue distribution by computed axial tomography in obese women: association with body density and anthropometric measurements. Br J Nutr 1989, 61:139-148.
19. Despre´s J.P., Ross R., Boka G., Alme´ras N., Lemieux I. Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the adagio-lipids trial. Arterioscler Thromb Vasc Biol 2009, 29:416-423.
20. Allain C.C., Poon L.S., Chan C.S., Richmond W., Fu P.C. Enzymatic determination of total serum cholesterol. Clin Chem 1974, 20:470-475.
21. Fossati P., Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 1982, 28:2077-2080.
22. Arsenault B.J., Lemieux I., Despre´s J.P., Wareham N.J., Luben R., Kastelein J.J., et al. Cholesterol levels in small LDL particles predict the risk of coronary heart disease in the epic-norfolk prospective population study. Eur Heart J 2007, 28:2770-2777.
23. Pe´russe M., Pascot A., Despre´s J.P., Couillard C., Lamarche B. A new method for HDL particle sizing by polyacrylamide gradient gel electrophoresis using whole plasma. J Lipid Res 2001, 42:1331-1334.
24. Borel A.L., Boulet G., Nazare J.A., Smith J., Alme´ras N., Tremblay A., et al. Improved plasma FFA/insulin homeostasis is independently associated with improved glucose tolerance after a 1-year lifestyle intervention in viscerally obese men. Diabetes Care 2013, 36:3254-3261.
25. Pelletier-Beaumont E., Arsenault B.J., Alme´ras N., Bergeron J., Tremblay A., Poirier P., et al. Normalization of visceral adiposity is required to normalize plasma apolipoprotein B levels in response to a healthy eating/physical activity lifestyle modification program in viscerally obese men. Atherosclerosis 2012, 221:577-582.
26. Kappelle P.J., Lambert G., Dullaart R.P. Plasma proprotein convertase subtilisin-kexin type 9 does not change during 24h insulin infusion in healthy subjects and type 2 diabetic patients. Atherosclerosis 2011, 214:432-435.
27. Awan Z., Delvin E.E., Levy E., Genest J., Davignon J., Seidah N.G., et al. Regional distribution and metabolic effect of PCSK9 insleu and R46L gene mutations and APOE genotype. Can J Cardiol 2013, 29:927-933.
28. Costet P., Cariou B., Lambert G., Lalanne F., Lardeux B., Jarnoux A.L., et al. Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. J Biol Chem 2006, 281:6211-6218.
29. Arsenault B.J., Beaumont E.P., Despre´s J.P., Larose E. Mapping body fat distribution: a key step towards the identification of the vulnerable patient?. Ann Med 2012, 44:758-772.
30. COˆte´ M., Maurie`ge P., Bergeron J., Alme´ras N., Tremblay A., Lemieux I., et al. Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. J Clin Endocrinol Metab 2005, 90:1434-1439.
31. Dubuc G., Chamberland A., Wassef H., Davignon J., Seidah N.G., Bernier L., et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2004, 24:1454-1459.
32. Borel A.L., Nazare J.A., Smith J., Almeras N., Tremblay A., Bergeron J., et al. Visceral and not subcutaneous abdominal adiposity reduction drives the benefits of a 1-year lifestyle modification program. Obes (Silver Spring) 2012, 20:1223-1233.